Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Neogenomics Inc (NEO)

Neogenomics Inc (NEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
HRB
3 Small-Cap Stocks with Questionable Fundamentals StockStory - Tue Jul 14, 11:33PM CDT

3 Small-Cap Stocks with Questionable Fundamentals

STC : 68.63 (-0.36%)
HRB : 41.14 (+0.49%)
NEO : 14.50 (+1.90%)
NEO
NeoGenomics (NEO) Stock Trades Up, Here Is Why StockStory - Thu Jul 9, 2:16PM CDT

NeoGenomics (NEO) Stock Trades Up, Here Is Why

NEO : 14.50 (+1.90%)
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer Business Wire - Thu Jul 9, 6:05AM CDT

Available within NEO PanTracer™ Pro for prostate cancer and as a standalone test, PTEN IHC CDx identifies patients who may be eligible for TRUQAP ®

NEO : 14.50 (+1.90%)
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026 Business Wire - Tue Jul 7, 6:05AM CDT

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2026 financial results...

NEO : 14.50 (+1.90%)
NEO
A Look Back at Testing & Diagnostics Services Stocks’ Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack StockStory - Thu Jun 25, 10:31PM CDT

A Look Back at Testing & Diagnostics Services Stocks’ Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack

NEO : 14.50 (+1.90%)
NeoGenomics Appoints Carolyn Starrett to its Board of Directors Business Wire - Thu Jun 25, 6:05AM CDT

NeoGenomics, Inc. (NASDAQ: NEO) , a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Carolyn Starrett to its...

NEO : 14.50 (+1.90%)
AMPL
1 Unprofitable Stock for Long-Term Investors and 2 Facing Headwinds StockStory - Thu Jun 18, 11:34PM CDT

1 Unprofitable Stock for Long-Term Investors and 2 Facing Headwinds

AMPL : 9.64 (-0.52%)
CNXC : 24.85 (+5.43%)
NEO : 14.50 (+1.90%)
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes Business Wire - Wed Jun 17, 5:00AM CDT

NeoGenomics, Inc. (NASDAQ: NEO) , a leading provider of oncology diagnostic solutions that enable precision medicine, announced today the pricing of its previously announced private offering of...

NEO : 14.50 (+1.90%)
NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes Business Wire - Mon Jun 15, 4:24PM CDT

NeoGenomics, Inc. (NASDAQ: NEO) , a leading provider of oncology diagnostic solutions that enable precision medicine, announced today that it has commenced a private offering of $275 million aggregate...

NEO : 14.50 (+1.90%)
NeoGenomics to Present New Research at ASCO Annual Meeting 2026 Business Wire - Tue May 26, 6:05AM CDT

Presentations highlight advances in MRD, precision oncology, and real-world evidence across solid tumors and hematologic malignancies

NEO : 14.50 (+1.90%)

Barchart Exclusives

This Dividend Stock Trading Near Multi-Year Lows Is a Risky Buy With Significant Upside Potential Barchart - Wed Jul 15, 6:30PM CDT
FMC stock is trading near the lowest level in over two decades as the company continues to battle several challenges. It, however, can be a speculative buy for aggressive investors given the low valuations. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.